- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02092142
Safety and Immunogenicity of Q Fever Vaccine
December 30, 2019 updated by: U.S. Army Medical Research and Development Command
Evaluation of the Safety and Immunogenicity of Q Fever Vaccine, Phase I, Inactivated, Dried, NDBR 105, in Subjects at Risk of Exposure to Coxiella Burnetii
The purpose of this study is to evaluate the safety of Q Fever Vaccine, Phase I, Inactivated, Dried, NDBR 105 and collect data on incidence of occupational Q fever infection in vaccinated personnel.
Study Overview
Study Type
Interventional
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Fort Deterick, Maryland, United States, 21702
- Special Immunizations Program, Division of Medicine, USAMRIID
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- At least 18 years old.
- Females of childbearing potential must agree to have a urine pregnancy test on the same day before receipt of skin test AND vaccine. (Exception: documented hysterectomy or ≥ 3 years of menopause.) The results must be negative. Females must agree to not become pregnant for 3 months after receipt of the skin test or vaccination.
- Considered at risk for exposure to C burnetii and who have submitted a Request for Investigational New Drug (IND) Vaccines for the Q Fever vaccine.
- Sign and date the approved informed consent document and Health Insurance Portability and Accountability Act (HIPAA) Authorization.
Have on their charts:
- Up-to-date medical history (including concomitant medications)
- Physical examination and laboratory tests within 1 year
- Previous chest x-ray and electrocardiogram
- Be medically cleared for participation by an investigator. Examinations or tests may be repeated at the discretion of the enrolling physician.
- Willing to return for all follow-up visits.
- Agree to report any adverse events (AEs) that may or may not be associated with administration of the test article for at least 28 days after vaccination and agree to report all serious adverse events (for example, resulting in hospitalization) for the duration of the subject's participation in the study (6 months).
- Agree to defer blood, bone marrow, and organ donation for 1 year after receipt of skin test antigen and/or vaccine.
Exclusion Criteria:
- Prior history of Q fever disease or vaccination.
- Clinically significant abnormal lab results (including evidence of hepatitis C, hepatitis B carrier state) or elevated liver function tests (two times the normal range or at the discretion of the principal investigator).
- Personal history of an immunodeficiency or current treatment with an oral or intravenous immunosuppressive medication.
- Confirmed HIV infection.
- Heart valve disease: prosthetic heart valve or clinically significant heart murmur. (If a murmur is detected on examination, an echocardiogram may be obtained or subject may be referred to a cardiologist to determine clinical significance.)
- Aneurysm/vascular graft.
- Joint prosthesis.
- History of chronic fatigue syndrome (or positive by chronic fatigue syndrome (CFS) Questionnaire criteria).
- Positive pregnancy test or breast-feeding female.
Any known allergies to components of the vaccine:
- Formalin
- Eggs or chicken products
- Administration of another vaccine or investigational product within 28 days of skin test and subsequent Q fever vaccination.
- Any unresolved AE resulting from a previous immunization.
- Transplant recipients, subjects with cancer, and those with chronic kidney disease.
- A medical condition that, in the judgment of the principal investigator, would impact subject safety.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Vaccinated
The vaccine will be administered subcutaneously in the upper outer aspect of the arm (triceps area) with 0.5 mL Q fever Vaccine, Phase I, Inactivated, Dried, NDBR 105 (which equals 30 μg)
|
Subcutaneous 0.5 mL Q fever Vaccine, Phase I, Inactivated, Dried, NDBR 105
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Immunogenicity
Time Frame: Day 28, Day 56, or 6 months
|
Immune response will be evaluated for per protocol subjects to determine the percentage of subjects who experience a ≥ fourfold rise in immunofluorescence assay (IFA) antibody titer after vaccination.
Immunoglobulin M (IgM) at Day 28 or Day 56, or immunoglobulin G (IgG) at 6 months.
|
Day 28, Day 56, or 6 months
|
Percentage of subjects with symptoms following Q fever vaccination
Time Frame: 6 months
|
6 months
|
|
Percentage of subjects with erythema following Q fever vaccination along with severity and association with vaccination
Time Frame: 6 months
|
6 months
|
|
Percentage of subjects with induration following Q fever vaccination along with severity and association with vaccination
Time Frame: 6 months
|
6 months
|
|
Percentage of subjects with each AE, system organ class of AE, severity, and association with vaccination
Time Frame: 6 months
|
6 months
|
|
Percentage of subjects with symptoms following Q fever skin test antigen
Time Frame: 6 months
|
6 months
|
|
Percentage of subjects with erythema following Q fever skin test antigen along with severity and association with skin test antigen
Time Frame: 6 months
|
6 months
|
|
Percentage of subjects with induration following Q fever skin test antigen along with severity and association with skin test antigen
Time Frame: 6 months
|
6 months
|
|
Percentage of subjects with each AE, system organ class of AE, severity, and association with skin test antigen
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Mark J Goldberg, MD, Special Immunizations Program, USAMRIID
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2006
Primary Completion (ANTICIPATED)
February 1, 2019
Study Completion (ANTICIPATED)
December 1, 2019
Study Registration Dates
First Submitted
March 17, 2014
First Submitted That Met QC Criteria
March 18, 2014
First Posted (ESTIMATE)
March 20, 2014
Study Record Updates
Last Update Posted (ACTUAL)
January 2, 2020
Last Update Submitted That Met QC Criteria
December 30, 2019
Last Verified
December 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- S-11-19
- FY13-02 (OTHER: MRMC)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Q Fever
-
Centre Hospitalier Universitaire de la RéunionCompleted
-
Jeroen Bosch ZiekenhuisZonMw: The Netherlands Organisation for Health Research and DevelopmentUnknownAneurysm | Aortic Aneurysm, Abdominal | Q Fever | Vascular Graft Infection | Chronic Q-feverNetherlands
-
University Medical Center GroningenZonMw: The Netherlands Organisation for Health Research and DevelopmentUnknown
-
Nantes University HospitalONIRISUnknown
-
U.S. Army Medical Research and Development CommandCompleted
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Cairo UniversityNot yet recruiting
-
University of PrimorskaBiovis d.o.o.CompletedCoenzyme Q DeficiencySlovenia
-
Cairo UniversityCompletedFekry VS the Air-Q Intubating AirwaysEgypt
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedFatigue Syndrome, Chronic | Q Fever | Coxiella InfectionNetherlands
Clinical Trials on Q fever Vaccine
-
U.S. Army Medical Research and Development CommandCompleted
-
Leiden University Medical CenterThe International Society of Travel MedicineRecruiting
-
EpicentreKenya Medical Research InstituteCompletedYellow FeverUganda, Kenya
-
London School of Hygiene and Tropical MedicineNot yet recruitingYellow Fever
-
Sanofi Pasteur, a Sanofi CompanyCompletedYellow Fever (Healthy Volunteers)United States
-
The Immunobiological Technology Institute (Bio-Manguinhos)...Ministry of Health, BrazilActive, not recruitingImmunity | Yellow Fever VaccineBrazil
-
Emory UniversityNational Institute of Allergy and Infectious Diseases (NIAID); National Institutes...Recruiting
-
Sanofi Pasteur, a Sanofi CompanyActive, not recruitingYellow Fever (Healthy Volunteers)United States
-
Sanofi Pasteur, a Sanofi CompanyActive, not recruitingStudy on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and AsiaYellow FeverGermany, France, Finland, Singapore, Spain, Thailand
-
University of Sao Paulo General HospitalCompletedRheumatoid Arthritis | Systemic Sclerosis | Granulomatosis With Polyangiitis | Juvenile Idiopathic Arthritis | Sjogren's Syndrome | Takayasu Arteritis | Spondyloarthritis | Juvenile Dermatomyositis | Mixed Connective Tissue Disease | Systemic Lupus | Inflammatory MyopathyBrazil